检索结果-南通市图书馆

In-situ Formation of Spinel Fibers in MgO-C refractory.Matrixes

Journal of Wuhan University of Technology(Materials Science) 2009年第6期24卷 896-902页

作者：谢朝晖 High Temperature Ceramics Institute Zhengzhou University

In-situ magnesia-rich spinel fiber was formed resulting from the addition of ferrocene into MgO-C refractory.matrixes. The formation of in-situ spinel fiber was detected to start at 1300 ℃. The amount, diameter and length of the fibers increased with rising temperature. Ferrocene may have catalytic effects on the growth of the fibers in two aspects. First, the reaction between MgO and C and the decomposition of Al4C3 may be catalyzed at high temperature. Suitable concentration gaseous phase is then created for vapor-vapor reaction which could result in the in-situ formation of fibers. Second, Fe nanoparticle produced from ferrocene can act as catalytic droplets and catalyze the growth of the fibers. The fibers are formed via the vapor-liquid-solid and vapor-solid mechanisms. In terms of chemical thermodynamics, the partial pressure of CO and Mg（g） are found to play an important role in the in-situ fibers formation. Different concentration of vapors affects the size, amount and composition of the fibers at different temperatures. The mechanical properties of MgO-C brick was found to be improved by ferrocene addition.

关键词： spinel fiber in-situ formation ferrocene MgO-C brick refractory.

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Pegylated Liposomal Doxorubicin as a Single Agent or as Combination Therapy with Carboplatin in Patients with Recurrent or refractory.Epithelial Ovarian Cancer

引用

Clinical oncology and cancer researeh 2009年第6期6卷 387-393页

作者： Beihua Kong Yunong Gao Lingying Wu Ziting Li Yile Chen Mengda Li Yongliang Gao Ding ga Zhilan Peng KengShen Peking Union Medical College Hospital Beijing China Shandong University Qilu Hospital Jinan Shandong Province China Beijing Oncology Hospital Beijing China Cancer Hospital and Institute Chinese Academy of Medical Sciences Beijing China Fudan University Cancer Hospital Shanghai China Hunan Province Oncology Hospital Changsha Hunan Province China Sun Yat-Sen University Cancer Center Guangzhou Guangdong Province China Zhejiang Province Oncology Hospital Hangzhou Zhejiang Province China Tongji Hospital of Tongji Medical College of Huazhong University of Science & Technology Wuhan Hubei Province China West China Second Hospital of Sichuan University Chengdu Sichuan Province

OBJECTIVE Pegylated liposomal doxorubicin （PLD; CAELYX ）, a novel formulation of doxorubicin with enhanced therapeutic efficacy and reduced toxicity, has demonstrated improved progression-free survival in recurrent or refractory.ovarian cancer. The objective of this open-label, noncomparative, observational study was to determine the efficacy and safety of PLD monotherapy or combination therapy with carboplatin for patients with cancer. recurrent or refractory.ovarian METHODS Sixty-two patients with recurrent or refractory.ovarian cancer who completed a platinum-based chemotherapy regimen and demonstrated platinum sensitivity for first-line treatment at least 6 months prior to study entry were enrolled in 20 centers in China. PLD was given as monotherapy （50 mg/m2 infused over 60 minutes） or as combination therapy （30 mg/m2 1-hour infusion） with carboplatin （area under the curve 5 ***/mL 1-hour infusion） on day 1 every 28 days for 4 cycles. The primary endpoint was objective response （OR） rate or CA-125 level. Secondary endpoints included time to response, time-to-progression, health-related quality of life, and safety. RESULTS Overall, 48% of the 62 evaluable patients achieved a confirmed OR. More patients receiving PLD and carboplatin achieved an OR vs the PLD monotherapy group （63% vs. 37%）. The median time to response and disease progression was 58.5 days and 56.0 days, respectively. Overall and drug-related adverse events were reported for 39% and 34%, respectively. The most commonly reported adverse events were stomatitis （22.6%） and palmar-plantar erythroderma （9.7%）. Two deaths were reported. CONCLUSION PLD is an effective and well tolerated agent in women with recurrent or refractory.epithelial ovarian cancer.

关键词： carboplatin ovarian cancer pegylated liposomal doxorubicin recurrent refractory.

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：